International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease

PURPOSE: Positron emission tomography (PET) with the first and only tau targeting radiotracer of (18)F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Mei, Civelek, A. Cahid, Carrio, Ignasi, Watanabe, Yasuyoshi, Kang, Keon Wook, Murakami, Koji, Garibotto, Valentina, Prior, John O., Barthel, Henryk, Zhou, Rui, Hou, Haifeng, Dou, Xiaofeng, Jin, Chentao, Zuo, Chuantao, Zhang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803772/
https://www.ncbi.nlm.nih.gov/pubmed/34978595
http://dx.doi.org/10.1007/s00259-021-05673-w
_version_ 1784642941369712640
author Tian, Mei
Civelek, A. Cahid
Carrio, Ignasi
Watanabe, Yasuyoshi
Kang, Keon Wook
Murakami, Koji
Garibotto, Valentina
Prior, John O.
Barthel, Henryk
Zhou, Rui
Hou, Haifeng
Dou, Xiaofeng
Jin, Chentao
Zuo, Chuantao
Zhang, Hong
author_facet Tian, Mei
Civelek, A. Cahid
Carrio, Ignasi
Watanabe, Yasuyoshi
Kang, Keon Wook
Murakami, Koji
Garibotto, Valentina
Prior, John O.
Barthel, Henryk
Zhou, Rui
Hou, Haifeng
Dou, Xiaofeng
Jin, Chentao
Zuo, Chuantao
Zhang, Hong
author_sort Tian, Mei
collection PubMed
description PURPOSE: Positron emission tomography (PET) with the first and only tau targeting radiotracer of (18)F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform (18)F-flortaucipir PET imaging. METHOD: A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for (18)F-flortaucipir PET imaging in Alzheimer’s disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting. CONCLUSION: This international consensus and practice guideline will help to promote the standardized use of (18)F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice.
format Online
Article
Text
id pubmed-8803772
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-88037722022-02-02 International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease Tian, Mei Civelek, A. Cahid Carrio, Ignasi Watanabe, Yasuyoshi Kang, Keon Wook Murakami, Koji Garibotto, Valentina Prior, John O. Barthel, Henryk Zhou, Rui Hou, Haifeng Dou, Xiaofeng Jin, Chentao Zuo, Chuantao Zhang, Hong Eur J Nucl Med Mol Imaging Guidelines PURPOSE: Positron emission tomography (PET) with the first and only tau targeting radiotracer of (18)F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology deposition and distribution in patients with cognitive impairment. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform (18)F-flortaucipir PET imaging. METHOD: A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for (18)F-flortaucipir PET imaging in Alzheimer’s disease (AD), focusing on clinical scenarios, patient preparation, and administered activities, as well as image acquisition, processing, interpretation, and reporting. CONCLUSION: This international consensus and practice guideline will help to promote the standardized use of (18)F-flortaucipir PET in patients with AD. It will become an international standard for this purpose in clinical practice. Springer Berlin Heidelberg 2022-01-03 2022 /pmc/articles/PMC8803772/ /pubmed/34978595 http://dx.doi.org/10.1007/s00259-021-05673-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Guidelines
Tian, Mei
Civelek, A. Cahid
Carrio, Ignasi
Watanabe, Yasuyoshi
Kang, Keon Wook
Murakami, Koji
Garibotto, Valentina
Prior, John O.
Barthel, Henryk
Zhou, Rui
Hou, Haifeng
Dou, Xiaofeng
Jin, Chentao
Zuo, Chuantao
Zhang, Hong
International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease
title International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease
title_full International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease
title_fullStr International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease
title_full_unstemmed International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease
title_short International consensus on the use of tau PET imaging agent (18)F-flortaucipir in Alzheimer’s disease
title_sort international consensus on the use of tau pet imaging agent (18)f-flortaucipir in alzheimer’s disease
topic Guidelines
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803772/
https://www.ncbi.nlm.nih.gov/pubmed/34978595
http://dx.doi.org/10.1007/s00259-021-05673-w
work_keys_str_mv AT tianmei internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT civelekacahid internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT carrioignasi internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT watanabeyasuyoshi internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT kangkeonwook internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT murakamikoji internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT garibottovalentina internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT priorjohno internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT barthelhenryk internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT zhourui internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT houhaifeng internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT douxiaofeng internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT jinchentao internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT zuochuantao internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT zhanghong internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease
AT internationalconsensusontheuseoftaupetimagingagent18fflortaucipirinalzheimersdisease

Ejemplares similares